Thorax Online First, published on November 22, 2006 as 10.1136/thx.2006.065482

Multilocus analysis of atopy in Korean children using multifactor-dimensionality reduction

Heung-Woo Park[1,2], Eun-Soon Shin[3], Jong-Eun Lee[3], Hyouk-Soo Kwon[1,2], Eunyoung Chun[1,2], Sun-Sin Kim[1,2], Yoon-Seok Chang[1,2], Yoon-Keun Kim[1,2,*], Kyung-Up Min[1,2], You-Young Kim[1,2], and Sang-Heon Cho[1,2]

[1]Department of Internal Medicine, [2]Institute of Allergy and Clinical Immunology, Seoul National University College of Medicine; [3]DNA Link Inc., Seoul, Republic of Korea
[*]Current address: Department of Life Science, Pohang University of Science and Technology, Pohang, Republic of Korea

Correspondence and requests for reprints should be addressed to Sang-Heon Cho, MD, PhD. Department of Internal Medicine, Seoul National University, 28 Yongondong, Chongno-gu, Seoul 110-744, Republic of Korea. E-mail: shcho@plaza.snu.ac.kr, Fax: 82-2-762-9662, Phone Number: 82-2-2072-2971

Keywords: Atopy, Gene-gene interaction, Tumor necrosis factor α, Vascular endothelial growth factor receptor 2

Abbreviations:
CV: Cross Validation
KDR: Kinase insert domain–containing receptor
MDR: Multifactor dimensionality reduction
SNP: Single nucleotide polymorphism
TNF: Tumor necrosis factor
VEGF: Vascular endothelial growth factor

Summary

Background: Atopy is considered to be a complex genetic trait and do not follow a simple Mendelian pattern of heritance. It is now well recognized that gene-gene interactions are important in complex genetic disease.

Methods: A total of 2,055 ethnically identical subjects aged from 10 to 18 years living in rural areas on Jeju Island, Korea were randomly recruited. Atopy was defined as a positive skin prick test response to one or more common inhalant allergen. We analyzed gene to gene interactions among 12 polymorphic loci in the 7 candidate genes of atopy using multidimensionality reduction method.

Results: A significant interaction was found between V297I in the gene coding vascular endothelial growth factor receptor 2 (*KDR*) and -308G>A in the gene coding tumor necrosis factor α (*TNF*) on the risk of atopy, with a cross-validation consistency of 10 of 10 and a prediction error of 35.9% (P = 0.001). Conventional logistic regression also revealed significant interactions between *KDR* and *TNF* for atopy. Individuals with the variant allele of -308G>A in *TNF* (GA or AA) and V297I in *KDR* (VI or II) had a significant higher risk of atopy [OR (95%CI) = 2.23 (1.48-3.57)].

Conclusion: *KDR* and *TNF* may synergistically influence on the development of atopy through gene-gene interaction in Korean children and adolescents.

Atopy is defined as a genetic predisposition to induce enhanced IgE responses to common environmental allergens. It is considered to be a complex genetic trait and thus do not follow a simple Mendelian pattern of heritance. Instead, the genetic determination of atopy is likely due to several genes, each having a small, possibly synergistic, effect on phenotype. Therefore it is necessary to consider simultaneously the effect of several single nucleotide polymorphism (SNP) genotypes at different loci. Such gene-gene interactions are traditionally evaluated using logistic regression. However procedures for fitting logistic regression model are problematic leading to an increase in type II errors and a decrease in power. In addition, sparseness of the data can be another problem in high dimensions.

To address these problems, multifactor dimensionality reduction or MDR has been developed.[1] MDR is a nonparametric and genetic model-free approach and is able to identify evidence for high-order gene–gene interactions in the absence of any statistically significant independent main effects in simulated data.[2,3] With MDR, gene-gene interactions has been revealed in complex genetic disorders, such as hypertension,[4] type 2 diabetes mellitus,[5] atrial fibrillation,[6] myocardial infarction[7] and asthma.[8]

In the present study, 12 loci in 7 genes proven to be related with atopy or enhanced serum IgE were genotyped in Korean children and adolescents and gene-gene interaction was examined with MDR.

Methods

Study subjects and atopy definition

All the subjects enrolled in this study gave written informed consent, and the study protocol was approved by the Institutional review board of Seoul National University Hospital. A total of 2,864 ethnically identical subjects aged from 10 to 18 years were randomly recruited through school located on the southern part of Jeju Island in Korea, of whom 2,055 (71.8%) were enrolled in this study. All of them resided in rural area and most of their parents lived by fishing or cultivating fruit trees. Skin prick test with 11 common aeroallergens (*Dermatophagoides pteronyssinus*, *Dermatophagoides farinae*, dog fur, cat fur, *Aspergillus*, *Alternaria*, tree pollen mixture, grass pollen mixture, mugwort, ragweed, and cockroach; Allergopharma, Germany) was performed as previously described[9]. Subjects who had received oral antihistamines during the five days prior to skin prick test or had dermographism were excluded. Atopy was defined as a positive skin prick test response (allergen/histamine ratio > 1.0 plus a mean wheal size > 4 mm) to one or more allergens.

Selection of genes and SNPs

On the assumption that cytokines play a crucial role in the widely used immunological model that explains the increasing prevalence of atopy by an altered balance between Th1 and Th2 immune responses,[10] we selected 6 cytokine-related candidate genes using public databases, e.g. PubMed and Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/Omim/). All have been characterized and potentially associated with atopy or enhanced serum IgE in asian population and subsequent studies performed in non-asian population have witnessed this association.[11-25] The only exception was *KDR* (Kinase insert domain–containing receptor) coding vascular endothelial growth factor (VEGF) receptor 2 which, in our previous study, was proven to be associated with increased prevalence of atopy in Korean population.[26] In addition to these cytokine-related genes, *MS4A2* coding high affinity IgE receptor beta subunit (FcεR1B) was included which was also known to be significantly associated with atopy.[27,28] Within these genes, 10 functional SNPs[11,12,14,17,18,29-31] were chosen for analysis. As for *KDR*, I297V and H472Q were selected because they were located in regions coding for the extracellular fourth and fifth immunoglobulin-like domains and thus possibly alter signaling pathway as discussed in our previous study.[26] Table 1 shows the list of SNPs analyzed in this study.

Genotyping

SNPs were scored using the high throughput single base-pair extension method (SNP-IT^{TM} assay) using an SNPstream25K system, which was customized to automatically genotype DNA samples in 384 well plates and provide a colorimetric readout (Orchid Biosciences, New Jersey, USA) as previously described.[26]

Statistical analysis

Allele frequencies were estimated by gene counting methods and the $\chi 2$ test was used to examine the Hardy-Weinberg equilibrium. Association between atopy and each 12 loci was made with the Pearson $\chi 2$ test with use of dominant, recessive and co-dominant genetic models. MDR (version 0.6.2; Computational Genetics Laboratory, Dartmouth Medical School, Hanover, NH; http://www.epistasis.org) was done as described previously[1-3,5,8]. Briefly, the data set is divided into ten parts of equal size for 10-fold cross-validation (CV) (9/10 of the data for training and 1/10 of the data for testing). Next, a set of *n* SNP polymorphisms is selected which are represented in *n*-dimensional space. Then the ratio of cases to controls is calculated for each combination, which is labeled 'high-risk' (> 1.0) or 'low-risk' (< 1.0). Consequently, *n* dimensional space was reduced to one dimension with two levels. Among all of the two-factor combinations, a single model that minimizes classification error is chosen. To evaluate the predictive ability of the model, a prediction error is obtained through 10-fold CV. In our study we set out to detect all two-locus interactions through five-locus interactions due to computation restrictions. From this set, the model with the combination of loci that maximizes the CV consistency and minimizes the prediction error is selected. We determined statistical significance of the final best model using 1000 permutation testings. The entire procedure is repeated for each, generating a distribution of predictive errors and CV consistencies that could be expected by chance alone. The significance of the final model is determined by comparing the predictive error and CV consistency of the final model to the distribution. A *P* value is extracted for the model by its theoretical location in the distribution. In addition, logistic regression analysis and $\chi 2$ tests were performed to confirm the results from MDR analyses. A *P* value of less than 0.05 was considered statistically significant. The detection power of the sample in the present study was 0.8 for atopy, if the relative risk for atopy in those persons carrying a putative risk allele is set to 2 compared with that in persons without the allele. The exception was S226N in *IL12B* (detection power was 0.6).

Results

Study population

A total of 2,055 children and adolescents were enrolled. The mean age was 14.6 (range; 10-18) and 48.9% of them were male. The characteristics of study population are shown in Table 2.

Association between atopy and individual SNP

All 12 SNPs examined in the present study were in Hardy-Weinberg equilibrium. The minor allele frequencies of SNPs in the present study with comparison to those previously reported are given in table S1 available online at the Thorax website http://www.thoraxjnl.com/supplemental. Among them, *MS4A2* E237G (P = 0.028 in a co-dominant model), *TNF* -308G>A [P = 0.031; odds ratio (95% CI) = 1.31 (1.02-1.69) in a dominant model] and *KDR* V297I [P =0.048; odds ratio (95% CI) = 1.22 (1.00-1.50) in a dominant model] showed significant association with atopy (Table 3).

MDR analysis

Table 4 summarizes, for each number of loci evaluated, the average CV consistency and average prediction error obtained from MDR analysis. One two-locus model had a minimum prediction error of 35.93% (P = 0.001) and a maximum CV consistency of 10 out of 10. This two-locus model which included *TNF* -308G>A and *KDR* V297I (figure 1) was regarded as the best model.

Logistic regression analysis

A significant interaction between *TNF* -308G>A and *KDR* V297I on the risk of atopy was also found by means of logistic regression analysis (P < 0.001), adjusting for age, sex, passive smoking and family history of allergic disease as covariates. Individuals with the variant allele of *TNF* -308G>A (GA or AA) and *KDR* V297I (VI or II) had a significant higher risk of atopy [OR (96%CI) = 2.30 (1.48-3.57)]. Table 5 shows the results.

Discussion

Perhaps the toughest problem faced by the allergist is that of identifying genes carrying alleles affecting liability to asthma or atopy from the vast field of potential candidates. The problem becomes even harder if gene-gene interaction must be considered. In the present study, a 2-locus model involving SNPs in *TNF* and *KDR* was identified by MDR as being associated with atopy. Moreover this was confirmed again by conventional logistic regression analysis.

So far, several investigators have witnessed gene-gene interactions in asthma or its related phenotypes using traditional procedures for fitting logistic regression models.[15,32] However, logistic regression analysis can be problematic leading to an increase in type II errors and a decrease in power. For example, forward selection is limited because interactions are only tested for those variables that have a statistically significant independent main effect. Those SNPs that have an interaction effect but not a main effect will be missed. Likewise only two SNPs with the strongest evidence for association with asthma phenotypes were selected in the previous studies. On the contrary, MDR is able to identify evidence for high order gene-gene interactions in the absence of the statistically significant independent main effects in diseases.[2,3] There was no *a prior* assumption on whether there was interaction between any specific combination of SNPs in the present study. Along with this, MDR effectively detected 2-locus interaction among 12 SNPs which showed no significant association with atopy individually after correction for multiple testing in the present study. We used 0.016 (0.05/3) as a Bonferroni corrected *P* value because we analyzed our findings at each locus under three models. The Bonferroni procedure is said to be conservative and thus will be unable to detect some of the actual differences. However, MDR procedure in the present study evidently finds genetic effects on atopy derived by gene-gene interactions which is much stronger than those caused by individual SNP.

Results of the present study are of particular interesting in that previous studies consistently reported that interaction between *IL4RA* and *IL13* markedly increased an individual's susceptibility to asthma.[8,15] Recently, Chan IH and his colleagues, using MDR analysis, showed a significant interaction between I50V in the *IL4RA* and R130Q in the *IL13* for asthma which were also included for analysis in the present study.[8] However, like us, they failed to demonstrate an interaction between *IL4RA* and *IL13* for total serum IgE concentration, another important intermediate phenotype of atopy. Taken together, these findings implied that, although atopy is known to be an important risk factor, additional or different genetic factors are needed for the development of

asthma.

The present study showed a new insight in the genetic basis for atopy, that is, a significant interaction between V297I in the *KDR* and -308G>A in the *TNF*. VEGF was originally described as a vascular permeability factor because of its ability to generate tissue edema and subsequently, it was appreciated to be a multifunctional angiogenic regulator that stimulates epithelial cell proliferation, blood vessel formation, and endothelial cell survival.[33] VEGF receptor 2 is known to be a major VEGF signaling receptor.[33] The ability of cockroach antigen to directly stimulate epithelial VEGF elaboration[34] may account for the impressive levels of sensitization that are caused by even low-level exposure to this antigen.[35] Moreover, our previous study demonstrated that V297I causing amino acid change in regions in the *KDR* which is known to be essential for maintaining the high association rate with VEGF and retention of the VEGF on the receptor, was significantly associated with the prevalence of atopy.[26] It is plausible that VEGF contributes to the proclivity of individuals to become sensitized to respiratory antigens and thus genetic variation in the *KDR* may have effects on the development of atopy. Tumor necrosis factor α (TNFα) is a potent proinflammatory cytokine that is thought to be associated with predisposition to atopy.[36] During early maturation of the infant's immune system, TNFα might be produced by antigen-presenting cells, such as monocytes-macrophages, dendritic cells[37] and mast cells,[38] playing an important role in the interactions between innate and adaptive immunity. Innate immune cytokines, such as TNFα, are likely involved in priming the adaptive immune-humoral responses. Notably, recent evidence has linked TNFα to the development of allergic rhinitis in mice.[39] Interestingly, it has been demonstrated that TNFα and VEGF react upon each other in inflammatory site; TNFα induces VEGF[40] and *vice versa*.[41] Collectively, *TNF* and *KDR* may synergistically influence on the development of atopy through gene-gene interaction.

Acknowledgements

This work was supported by the Korea Health 21 R&D Project Grant 03-PJ10-PG13-GD01-0002 and the Clinical Research Center for Chronic Obstructive Airway Disease Grant 0412-CR03-0704-0001from the Korean Ministry of Health and Welfare.

References

1. **Hahn LW**, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. *Bioinformatics* 2003;**19**:376-82.

2. **Ritchie MD**, Hahn LW, Roodi N, et al**.** Multifactor dimensionality reduction reveals high-order interactions among estrogen metabolism genes in sporadic breast cancer. *Am J Hum Genet* 2001;**69**:138-47.

3. **Moore JH**, Williams SW. New strategies for identifying gene–gene interactions in hypertension. *Ann Med* 2002;**34**:88-95.

4. **Williams SM**, Ritchie MD, Phillips JA III, et al. Multilocus analysis of hypertension: a hierarchical approach. *Hum Hered* 2004;**57**:28-38.

5. **Cho YM**, Ritchie MD, Moore JH, et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with type 2 diabetes mellitus. *Diabetologia* 2004;**47**:549-54.

6. **Tsai CT**, Lai LP, Lin JL, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. *Circulation* 2004;**109**:1640-6.

7. **Coffey CS**, Hebert PR, Ritchie MD, et al. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. *BMC Bioinformatics* 2004;**5**:49-59.

8. **Chan IH**, Leung TF, Tang NL, et al**.** Gene-gene interactions for asthma and plasma total IgE concentration in Chinese children. *J Allergy Clin Immunol* 2006;**117**:127-33.

9**. Kim YK**, Chang YS, Lee MH, et al. Role of environmental exposure to spider mites in the sensitization and the clinical manifestation of asthma and rhinitis in children and adolescents living in rural and urban areas. *Clin Exp Allergy* 2002;**32**:1305-9.

10. **Yazdanbakhsh M,** Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. *Science* 2002**;296:**490-4**.**

11. **Hershey GK**, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. *N Engl J Med* 1997;**337**:1720-5.

12. **Risma KA**, Wang N, Andrews RP, et al. V75R576 IL-4 receptor alpha is associated with allergic asthma and enhanced IL-4 receptor function. *J Immunol* 2002;**169**:1604-10.

13. **Heinzmann A**, Mao XQ, Akaiwa M, et al. Genetic variants of IL-13 signalling and human asthma and atopy. *Hum Mol Genet* 2000;**9**:549-59.

14. **Mitsuyasu H**, Izuhara K, Mao XQ, et al. Ile50Val variant of IL4Ra upregulates IgE

synthesis and associates with atopic asthma. *Nat Genet* 1998;**19**:119-20.
15. **Howard TD**, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. *Am J Hum Genet* 2002;**70**:230-6.
16. **Leung TF,** Tang NL, Chan IH, et al. A polymorphism in the coding region of interleukin-13 gene is associated with atopy but not asthma in Chinese children. *Clin Exp Allergy* 2001;**31**:1515-21.
17. **van der Pouw Kraan TC,** van Veen A, Boeije LC, et al. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. *Genes Immun* 1999;**1**:61-5.
18. **Vladich FD**, Brazille SM, Stern D, et al. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. *J Clin Invest* 2005;**115**:747-54.
19. **Gao J**, Shan G, Sun B, et al. Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. *Thorax* 2006;**61:**466-71.
20. **Wang TN**, Chen WY, Wang TH, et al. Gene-gene synergistic effect on atopic asthma: tumour necrosis factor-alpha-308 and lymphotoxin-alpha-NcoI in Taiwan's children. *Clin Exp Allergy* 2004;**34**:184-8.
21. **Shin HD**, Park BL, Kim LH, et al. Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. *Hum Mol Genet* 2004;**13**:397-403.
22. **Hirota T**, Suzuki Y, Hasegawa K, et al. Functional haplotypes of IL-12B are associated with childhood atopic asthma. *J Allergy Clin Immunol* 2005;**116**:789-95.
23. **Randolph AG**, Lange C, Silverman EK, et al. The IL12B gene is associated with asthma. *Am J Hum Genet* 2004;**75:**709-15.
24. **Joos L**, Carlen Brutsche IE, Laule-Kilian K, et al. Systemic Th1- and Th2-gene signals in atopy and asthma. *Swiss Med Wkly* 2004;**134**:159-64.
25. **Takahashi N,** Akahoshi M, Matsuda A, et al. Association of the IL12RB1 promoter polymorphisms with increased risk of atopic dermatitis and other allergic phenotypes. *Hum Mol Genet* 2005;**14**:3149-59.
26. **Park HW**, Lee JE, Shin ES, et al. Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population. *J Allergy Clin Immunol* 2006;**117**:774-9**.**
27. **Hill MR**, Cookson WO. A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. *Hum Mol Genet* 1996;**5**:959-62.
28. **Hizawa N**, Yamaguchi E, Jinushi E, et al. A common FCER1B gene promoter polymorphism influences total serum IgE levels in a Japanese population. *Am J Respir*

Crit Care Med 2000;**161**:906-9.
29. **Hytonen AM**, Lowhagen O, Arvidsson M, et al. Haplotypes of the interleukin-4 receptor alpha chain gene associate with susceptibility to and severity of atopic asthma. *Clin Exp Allergy* 2004;**34**:1570-5.
30. **Seegers D**, Zwiers A, Strober W, et al. A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. *Genes Immun* 2002;**3**:419-23.
31. **Akahoshi M**, Nakashima H, Miyake K, et al. Influence of interleukin-12 receptor beta1 polymorphisms on tuberculosis. *Hum Genet* 2003;**112:**237-43.
32. **Hong SJ**, Lee SY, Kim HB, et al. IL-5 and thromboxane A2 receptor gene polymorphisms are associated with decreased pulmonary function in Korean children with atopic asthma. *J Allergy Clin Immunol* 2005;**115**:758-63.
33. **Clauss M**. Molecular biology of the VEGF and the VEGF receptor family. *Semin Thromb Hemost* 2000;**26**:561-9.
34. **Antony AB**, Tepper RS, Mohamed KA. Cockroach extract antigen increases bronchial epithelial permeability. *J Allergy Clin Immunol* 2002;**110**;589-95.
35. **Matsui EC**, Wood RA, Rand C, et al. Cockroach allergen exposure and sensitization in suburban middle-class children with asthma *J Allergy Clin Immunol* 2003;**112**:87-92.
36. **Wright RJ**, Finn P, Contreras JP, et al. Chronic caregiver stress and IgE expression, allergen-induced proliferation, and cytokine profiles in a birth cohort predisposed to atopy. *J Allergy Clin Immunol* 2004;**113**:1051-7.
37. **Fearon DT**, Locksley RM. The instructive role of innate immunity in the acquired immune response. *Science* 1996;**272**:50-3.
38. **Okumura S**, Kashiwakura J, Tomita H, et al. Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcepsilonRI. *Blood* 2003;**10**:2547-54.
39. **Iwasaki M**, Saito K, Takemura M, et al. TNF-alpha contributes to the development of allergic rhinitis in mice. *J Allergy Clin Immunol* 2003;**112**:134-40.
40. **Hangai M**, He S, Hoffmann S, et al. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells *J Neuroimmunol* 2006;**171**:45-56.
41. **Yoo SA**, Bae DG, Ryoo JW, et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. *J Immunol* 2005;**174**:5846-55.

Table 1. Candidate genes and SNPs analyzed in this study

Gene	SNP	rs number	Association
IL4R	-3223T>C	rs2057768	atopy[11-13], IgE[14]
	Q576R	rs1801275	
	I75V	rs1805010	
IL13	-1510A>C	rs1881457	atopy[16,17], IgE[15,18]
	-1111C>T	rs1800925	
	Q144R	rs20541	
TNF	-308G>A	rs1800629	atopy[19,20], IgE[21]
IL12B	S226N	-	atopy[22,23]
IL12RB1	M365T	rs375947	atopy[24,25]
*KDR**	V297I	rs2305948	atopy[26]
	H472Q	rs1870377	
MS4A2†	E237G	rs569108	atopy[27,28], IgE[27,28]

* *KDR*: gene coding vascular growth factor receptor 2

† *MS4A2*: gene coding high affinity IgE receptor beta subunit

Table 2. The characteristics of study population

Characteristics	Number of positivity (%)
Age, mean (range)	14.6 (10-18)
Male	1004 (48.9)
Atopy*	767 (37.3)
History of passive smoking	1342 (65.3)
Family history of allergic disease	376 (18.3)
Vaccination history	1552 (75.5)

* Positive skin test responses to one or more common aeroallergens

Table 3. Genetic effects of individual SNP on atopy

	Genotype frequency			*P* value*		
				Dominant†	Recessive†	Co-dominant†
IL4R						
-3223T>C						
	TT	TC	CC			
Atopy	278 (38.0%)	346 (47.3%)	108 (14.7%)	0.130	0.413	0.301
Control	515 (41.4%)	561 (45.1%)	167 (13.5%)			
Q576R						
	QQ	QR	RR			
Atopy	529 (69.2%)	214 (28.0%)	21 (2.8%)	0.831	0.426	0.728
Control	890 (69.1%)	357 (27.7%)	41 (3.2%)			
V75I						
	VV	VI	II			
Atopy	244 (31.9%)	378 (49.5%)	142 (18.6%)	0.789	0.283	0.214
Control	460 (35.7%)	615 (47.7%)	213 (16.6%)			
IL13						
-1510A>C						
	AA	AC	CC			
Atopy	381 (53.4%)	267 (37.5%)	65 (9.1%)	0.630	0.170	0.248
Control	646 (52.3%)	498 (40.3%)	91 (7.4%)			
-1111C>T						
	CC	CT	TT			
Atopy	478 (67.3%)	203 (28.6%)	29 (4.1%)	0.614	0.907	0.880
Control	805 (66.2%)	360 (29.6%)	51 (4.2%)			
R130Q						
	RR	RQ	QQ			
Atopy	364 (47.5%)	334 (43.5%)	69 (9.0%)	0.631	0.891	0.853
Control	628 (48.7%)	546 (42.4%)	114 (8.9%)			
TNF						
-308G>A						
	GG	GA	AA			
Atopy	606 (82.6%)	126 (17.2%)	2 (0.2%)	0.031	0.857	0.043
Control	1083 (86.2%)	170 (13.5%)	4 (0.3%)			
KDR						
V297I						

	VV	VI	II			
Atopy	543 (71.3%)	206 (27.1%)	12 (1.6%)	0.048	0.212	0.029
Control	972 (75.4%)	286 (22.2%)	30 (2.4%)			
H472Q						
	HH	HQ	QQ			
Atopy	256 (33.7%)	355 (46.8%)	148 (19.5%)	0.559	0.698	0.827
Control	451 (35.1%)	597 (46.4%)	240 (18.5%)			
IL12B						
S226N						
	SS	SN	NN			
Atopy	724 (94.4%)	43 (5.6%)	0 (0%)	0.744	-	0.748
Control	1230 (95.5%)	58 (4.5%)	0 (0%)			
IL12RB1						
M365T						
	MM	MT	TT			
Atopy	247 (32.8%)	351 (46.6%)	155 (20.6%)	0.845	0.555	0.767
Control	420 (32.4%)	624 (48.1%)	253 (19.5%)			
MS4A2						
E237G						
	EE	EG	GG			
Atopy	568 (80.8%)	120 (17.7%)	15 (1.5%)	0.076	0.129	0.028
Control	936 (77.4%)	259 (21.4%)	15 (1.2%)			

*P values for logistic analyses controlling age, sex, a family history of allergic diseases, passive smoking history, and vaccination history

†Dominant model (AA *vs*. AB+BB), Recessive model (AA+AB *vs*. BB), and Co-dominant model (AA *vs*. AB *vs*. BB), where A is the major frequency allele and B is the minor frequency allele

Table 4. Summary of multiloci interaction for atopy by MDR analysis

No. of loci	Combination of SNPs	CV consistency	Prediction error (%)
2	-308G>A (*TNF*), V297I (*KDR*)	10	35.93
3	-308G>A (*TNF*), V297I (*KDR*), Q576R (*IL4R*)	3	35.44
4	E237G (*MS4A2*), V297I (*KDR*), I75V (*IL4R*), -1510A>C (*IL13*)	4	39.39
5	I75V (*IL4R*), R130Q (*IL13*), M365T (*IL12RB1*), H472Q (*KDR*), S226N (*IL12B*)	8	39.41

Table 5. Interactions between *TNF* and *KDR* genotypes for atopy

Genotype		Phenotype		*P* value*	OR (95%CI)
TNF (-308G>A)	*KDR* (V297I)	atopy	control		
GG	VV	434 (35.0%)	806 (65.0%)		1
GG	VI or II	81 (37.5%)	135 (62.5%)	0.53	1.11 (0.83-1.50)
GA or AA	VV	166 (38.5%)	265 (61.5%)	0.21	1.16 (0.93-1.46)
GA or AA	VI or II	47 (55.3%)	38 (44.7%)	< 0.001	2.30 (1.48-3.57)

**P* values for logistic analyses controlling age, sex, a family history of allergic diseases, passive smoking history, and vaccination history

Table S1. The minor allele frequencies of SNPs compared to those reported previously

SNP	Minor allele frequency	
	Present study	Previous reports (population and reference)
IL4R		
-3223T>C	37.2 %	10.7 % (Swedish healthy adults, ref. 29)
Q576R	16.8 %	22.0 % (Japanese healthy adults, ref. 13)
		30.5 % (American asthmatics, ref. 12)
I75V	41.6 %	40.4 % (Japanese healthy adults, ref. 14)
		42.0 % (American asthmatics, ref. 12)
IL13		
-1510A>C	28.0 %	22.0 % (American healthy adults, ref. 15)
-1111C>T	18.9 %	23.0 % (American healthy adults, ref. 15)
Q144R	30.8 %	40.8 % (Chinese healthy children, ref. 16)
		26.7 % (British healthy adults, ref. 13)
TNF		
-308G>A	7.7 %	7.0 % (Taiwanese healthy children, ref. 20)
		12.9 % (Czech healthy adults, ref. 19)
IL12B		
S226N	3.6 %	4.0 % (Japanese asthmatics‡)
IL12RB1		
M365T	33.0 %	36.2 % (Japanese healthy adults, ref. 31)
KDR*		
V297I	14.2 %	-
H472Q	42.6 %	-
MS4A2†		
E237G	11.7 %	5.3 % (Australian healthy adults, ref. 27)
		11.5 % (Japanese healthy adults¶)

* *KDR*: gene coding vascular growth factor receptor 2

† *MS4A2*: gene coding high affinity IgE receptor beta subunit

‡ **Noguchi E**, Yokouchi Y, Shibasaki M, et al. Identification of missense mutation in the IL12B gene: lack of association between IL12B polymorphisms and asthma and allergic rhinitis in the Japanese population. *Genes Immun* 2001;**2**:401-3

¶ **Nagata H**, Mutoh H, Kumahara K, et al. Association between nasal allergy and a coding variant of the Fc epsilon RI beta gene Glu237Gly in a Japanese population. *Hum Genet* 2001;**109**:262-6

Figure legends

Figure 1. Distribution of high-risk and low-risk genotypes in the best two-locus model. This summary of the distribution shows high-risk (dark shading) and low-risk (light shading) genotypes associated with atopy in the two-locus interaction detected by MDR analysis. The percentage of atopic subjects (left black bar in boxes) and control subjects (right hatched bar in boxes) is shown for each two-locus genotype combination. The white boxes are unclassified.


TNF (-308G>A)
GG
GA
AA
KDR (V297I)
VV
VI
II
60.5%
64.7%
11.1%
10.6%
0.1%
0.2%
22.3%
19.5%
5.7%
2.6%
0.1%
0.1%
0.1%
1.8%
0.1%
0.5%
0%
0%